Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.

39 Our animal PK data of Dox-NP ( Figure 4 ) agrees with the highly significant improvement in the PK and tumor levels of DOX in clinical Doxil treatment studies. 39 , 66 − 68 For instance, the clinical PK studies demonstrate an initial DOX distribution phase with a t 1/2 of 1–3 h, followed by a second distribution phase with a t 1/2 of 20–90 h. 39 , 66 − 68 Moreover, the “are

also in 132,142 other papers